Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allosamizoline is a synthetic small molecule and a cyclitol derivative featuring a fused dimethylaminooxazoline ring. It is structurally related to the natural product allosamidin and has been reported as an experimental compound with no approved medical indications. Allosamizoline has been identified in Streptomyces species and studied primarily for its biochemical properties rather than clinical use. Its mechanism of action is not fully characterized in humans; however it is known as a structural component or analog in research on chitinase inhibitors due to its similarity to allosamidin derivatives[1][2][7]. There are no approved therapeutic uses or clinical trials involving this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on allosamizoline.